Full name
CSL BEHRING SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
46.46.Z - Wholesale trade of pharmaceutical and medical products
47.73.Z - Retail sale of pharmaceutical products
73.20.Z - Market research and public opinion polling
82.30.Z - Activities related to organizing fairs, exhibitions, and congresses
82.99.Z - Other business support activities, not elsewhere classified
2022 | 2023 | 2024 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 3,9 | 3,2 | 15,1 | 365,8 |
EBITDA | 4,7 | 4,1 | 14,9 | 263,9 |
Short time liabilities | 64,6 | 80 | 64,6 | -19,2 |
Equity capital | 21,8 | 24,4 | 36,5 | 49,8 |
Operating profit (EBIT) | 4,4 | 3,8 | 14,7 | 288,4 |
Assets | 88,7 | 110,2 | 106,9 | -3 |
Net profit (loss) | 3 | 2,6 | 12,1 | 369,5 |
Cash | 9,3 | 3,8 | 4,8 | 27,3 |
Net income from sale | 163 | 224,1 | 247,2 | 10,3 |
Liabilities and provisions for liabilities | 66,9 | 85,8 | 70,3 | -18 |
Working assets | 87,9 | 108,7 | 105,5 | -3 |
Depreciation | 0,3 | 0,3 | 0,2 | -23,4 |
% | % | % | p.p. | |
Profitability of capital | 14 | 10,6 | 33,2 | 22,6 |
Equity capital to total assets | 24,6 | 22,1 | 34,2 | 12,1 |
Gross profit margin | 2,4 | 1,4 | 6,1 | 4,7 |
EBITDA Margin | 2,9 | 1,8 | 6 | 4,2 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 145 | 130 | 95 | -35 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane